Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate a well-characterized, commercially available
cinnamon dietary supplement as a precipitant of pharmacokinetic interactions with CYP2A6
substrates in healthy volunteers. Nicotine gum will be used as the CYP2A6 probe drug (i.e.,
positive control) and letrozole as a high-impact object drug. Results will be used to inform
future research on the potential use of cinnamon as a smoking cessation agent, as well as the
clinical impact on pharmacotherapeutic regimens involving letrozole in cancer patients.
Phase:
Early Phase 1
Details
Lead Sponsor:
Washington State University
Collaborators:
National Center for Complementary and Integrative Health (NCCIH) Office of Dietary Supplements (ODS)